Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Oncology Institute (TOI) Interest Expenses (2021 - 2025)

Oncology Institute's Interest Expenses history spans 5 years, with the latest figure at $1.9 million for Q4 2025.

  • For Q4 2025, Interest Expenses rose 64.04% year-over-year to $1.9 million; the TTM value through Dec 2025 reached $11.3 million, up 50.43%, while the annual FY2025 figure was $11.3 million, 50.43% up from the prior year.
  • Interest Expenses reached $1.9 million in Q4 2025 per TOI's latest filing, roughly flat from $1.9 million in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $5.6 million in Q1 2025 to a low of $61000.0 in Q2 2022.
  • Average Interest Expenses over 5 years is $1.6 million, with a median of $1.9 million recorded in 2025.
  • Peak YoY movement for Interest Expenses: soared 2585.25% in 2023, then plummeted 39.82% in 2024.
  • A 5-year view of Interest Expenses shows it stood at $81000.0 in 2021, then decreased by 24.69% to $61000.0 in 2022, then skyrocketed by 3081.97% to $1.9 million in 2023, then tumbled by 39.82% to $1.2 million in 2024, then skyrocketed by 64.04% to $1.9 million in 2025.
  • Per Business Quant, the three most recent readings for TOI's Interest Expenses are $1.9 million (Q4 2025), $1.9 million (Q3 2025), and $1.9 million (Q2 2025).